Kantum Pharma
Kantum Pharma is a privately held, preclinical-stage biotechnology company developing a therapeutic candidate for Acute Kidney Injury (AKI), targeting critical care clinicians. Founded in 2016 and based in Concord, New Hampshire, the company has raised approximately $3.53M to date.
- Company typePrivate
- Founded2016
- HeadquartersConcord, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Kantum Pharma firmographics
Firmographics- Name
- Kantum Pharma
- Legal name
- Kantum Pharma, Inc.
- Website
- https://kantumpharma.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Kantum Pharma is a privately held, preclinical-stage biotechnology company developing a therapeutic candidate for Acute Kidney Injury (AKI), targeting critical care clinicians. Founded in 2016 and based in Concord, New Hampshire, the company has raised approximately $3.53M to date.
- Ownership category
- akta.pro rank
Kantum Pharma industry classification
Industry- Product category
- Acute Kidney Injury Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Acute Kidney Injury (AKI) & Hospital Nephrology (Inpatient Consults) (HLAKAHAI)
- akta.pro secondary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where Kantum Pharma is headquartered
LocationHeadquarters
- HQ city
- Concord
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kantum Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Kantum Pharma product offering
Product offeringCore offering
Kantum Pharma is a biotechnology company developing a specific therapy for Acute Kidney Injury (AKI) intended to help critical care clinicians prevent hundreds of thousands of deaths caused by AKI. The company operates in the AKI clinical trial pipeline and is pre-commercial, with its offering centered on a single AKI therapeutic candidate.
Differentiator
Problem solved
Functional benefit
Products and services
- AKI Therapeutic (development-stage)
Companies that use Kantum Pharma
Customer profileIdeal customer profiles1 record
Kantum Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Kantum Pharma partnerships and signals
Strategic signalScale indicators1 record
Kantum Pharma competitors and assessment
Company assessmentDirect peers
- AM-Pharma: Dutch clinical-stage biotech developing recombinant alkaline phosphatase (ilofotenase) for AKI, the most directly comparable AKI-focused therapy developer and a clear head-to-head competitor for Kantum's indication.
- Atox Bio: Clinical-stage biotech developing therapeutics for critically ill patients including AKI and sepsis-associated kidney injury, with overlapping critical care nephrology focus.
- Thrasos Therapeutics: AKI therapeutics developer (acquired by Torrent Pharmaceuticals) that previously advanced a clinical-stage AKI candidate, illustrating both the competitive set and exit pathway for AKI-focused biotechs.
- Quark Pharmaceuticals: Clinical-stage RNA therapeutics company with programs in AKI and renal protection, pursuing similar indication spaces through a comparable early-stage development model.
- Angion Biomedica: Clinical-stage biotech focused on renal disease and AKI, developing small molecule and biologic therapies targeting kidney injury pathways overlapping with Kantum's therapeutic focus.
- Guard Therapeutics (Guardia): Swedish biotech developing RMC-035 for AKI and cardiac surgery-associated kidney injury, directly competing in the same therapeutic area with a similar clinical-stage profile.
Broad incumbents
- Alexion Pharmaceuticals (AstraZeneca Rare Disease): Large rare disease biopharma with established nephrology franchise (e.g., aHUS, atypical hemolytic uremic syndrome), representing a potential strategic acquirer and broad incumbent in renal therapeutics.
Emerging players
- Astute Medical (bioMérieux): Developer of the NEPHROCHECK Test, the leading FDA-cleared AKI biomarker diagnostic, adjacent to Kantum's therapeutic focus with overlapping critical care nephrology customer base.
Market position
Customer concentration
Kantum Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kantum Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Kantum Pharma funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kantum Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kantum Pharma
What does Kantum Pharma do?
Kantum Pharma is a biotechnology company developing a specific therapy for Acute Kidney Injury (AKI) intended to help critical care clinicians prevent hundreds of thousands of deaths caused by AKI. The company operates in the AKI clinical trial pipeline and is pre-commercial, with its offering centered on a single AKI therapeutic candidate.
Is Kantum Pharma a public or private company?
Kantum Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kantum Pharma founded?
Kantum Pharma was founded in 2016. It employs 1 to 10 people.
Where is Kantum Pharma based?
Kantum Pharma is headquartered in Concord, United States, in the North America region.
Who are Kantum Pharma's main competitors?
Direct peers on record are AM-Pharma, Atox Bio, Thrasos Therapeutics, Quark Pharmaceuticals, Angion Biomedica and Guard Therapeutics (Guardia). Alexion Pharmaceuticals (AstraZeneca Rare Disease) is listed as a broad incumbent. Astute Medical (bioMérieux) is listed as an emerging player.
Does Kantum Pharma have an API?
No public API is recorded for Kantum Pharma.
What industry is Kantum Pharma in?
Kantum Pharma's product category is Acute Kidney Injury Therapeutics. Its primary akta.pro industry code is HLAKAHAI, Acute Kidney Injury (AKI) & Hospital Nephrology (Inpatient Consults), with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.